This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Phase 1b Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Cascadian Therapeutics Inc.
ClinicalTrials.gov Identifier:
NCT02025192
First received: December 17, 2013
Last updated: August 10, 2017
Last verified: August 2017
  Purpose
The purpose of this study is to determine the maximal tolerated dose (MTD) or recommended phase 2 dose (RP2D) of tucatinib (ONT-380) and to assess the safety and tolerability of tucatinib (ONT-380) combined with capecitabine alone, trastuzumab alone and with both capecitabine and trastuzumab in patients with HER2+ metastatic breast cancer.

Condition Intervention Phase
HER2 Positive Metastatic Breast Cancers Drug: Tucatinib Drug: Capecitabine Drug: Trastuzumab Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Capecitabine and Trastuzumab, Alone and in Combination in HER2+ Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by Cascadian Therapeutics Inc.:

Primary Outcome Measures:
  • Incidence of adverse events [ Time Frame: 26 months ]
  • Severity of adverse events [ Time Frame: 26 months ]

Secondary Outcome Measures:
  • Incidence of clinical lab abnormalities (hematology, chemistry, liver function tests, coagulation, urinalysis) [ Time Frame: 26 months ]
  • Severity of clinical lab abnormalities (hematology, chemistry, liver function tests, coagulation, urinalysis) [ Time Frame: 26 months ]
  • Frequency of dose reductions in tucatinib (ONT-380) (%) [ Time Frame: 26 months ]
  • Frequency of dose reductions in capecitabine (%) [ Time Frame: 26 months ]
  • Plasma concentrations of tucatinib (ONT-380) and metabolite [ Time Frame: 26 months ]
  • Plasma concentrations of capecitabine and metabolites [ Time Frame: 26 months ]
  • Objective response rate (ORR) (%) [ Time Frame: 26 months ]
  • Duration of response (days) [ Time Frame: 26 months ]
  • Disease control rate (best response of CR, PR, or SD) (%) [ Time Frame: 26 months ]
  • Clinical benefit rate (CBR) (SD for ≥ 6 months, PR, or SR) (%) [ Time Frame: 26 months ]
  • Progression-free survival (PFS) (days) [ Time Frame: 26 months ]

Enrollment: 60
Study Start Date: December 2013
Estimated Study Completion Date: July 2018
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tucatinib (ONT-380) in combination with capecitabine Drug: Tucatinib
Phase 1b dose escalation: 21-day cycles of tucatinib (ONT-380) and capecitabine, tucatinib (ONT-380) and trastuzumab, and tucatinib (ONT-380), capecitabine and trastuzumab until disease progression or unacceptable toxicity. Tucatinib (ONT-380) and capecitabine are administered twice per day, orally. Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
Other Name: ONT-380
Drug: Capecitabine
Phase 1b dose escalation: 21-day cycles of tucatinib (ONT-380) and capecitabine, tucatinib (ONT-380) and trastuzumab, and tucatinib (ONT-380), capecitabine and trastuzumab until disease progression or unacceptable toxicity. Tucatinib (ONT-380) and capecitabine are administered twice per day, orally. Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
Other Name: Xeloda
Experimental: Tucatinib (ONT-380) in combination with trastuzumab Drug: Tucatinib
Phase 1b dose escalation: 21-day cycles of tucatinib (ONT-380) and capecitabine, tucatinib (ONT-380) and trastuzumab, and tucatinib (ONT-380), capecitabine and trastuzumab until disease progression or unacceptable toxicity. Tucatinib (ONT-380) and capecitabine are administered twice per day, orally. Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
Other Name: ONT-380
Drug: Trastuzumab
Phase 1b dose escalation: 21-day cycles of tucatinib (ONT-380) and capecitabine, tucatinib (ONT-380) and trastuzumab, and tucatinib (ONT-380), capecitabine and trastuzumab until disease progression or unacceptable toxicity. Tucatinib (ONT-380) and capecitabine are administered twice per day, orally. Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
Other Name: Herceptin
Experimental: Tucatinib (ONT-380) combined with capecitabine and trastuzumab Drug: Tucatinib
Phase 1b dose escalation: 21-day cycles of tucatinib (ONT-380) and capecitabine, tucatinib (ONT-380) and trastuzumab, and tucatinib (ONT-380), capecitabine and trastuzumab until disease progression or unacceptable toxicity. Tucatinib (ONT-380) and capecitabine are administered twice per day, orally. Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
Other Name: ONT-380
Drug: Capecitabine
Phase 1b dose escalation: 21-day cycles of tucatinib (ONT-380) and capecitabine, tucatinib (ONT-380) and trastuzumab, and tucatinib (ONT-380), capecitabine and trastuzumab until disease progression or unacceptable toxicity. Tucatinib (ONT-380) and capecitabine are administered twice per day, orally. Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
Other Name: Xeloda
Drug: Trastuzumab
Phase 1b dose escalation: 21-day cycles of tucatinib (ONT-380) and capecitabine, tucatinib (ONT-380) and trastuzumab, and tucatinib (ONT-380), capecitabine and trastuzumab until disease progression or unacceptable toxicity. Tucatinib (ONT-380) and capecitabine are administered twice per day, orally. Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
Other Name: Herceptin

Detailed Description:

This is a Phase 1b, open-label study of tucatinib (ONT-380) given in combination with capecitabine alone, trastuzumab alone and with both capecitabine and trastuzumab in patients with HER2+ metastatic breast cancer.

Phase 1 will use a 3+3 dose escalation design to evaluate escalating dose levels of tucatinib (ONT-380) in each of these three combinations in order to identify the maximal tolerated dose/recommended phase 2 dose (MTD/RP2D) of tucatinib (ONT-380). Capecitabine will be given at 1000 mg/m2 PO BID on Days 1-14 of each 21-day cycle. Trastuzumab will be given as a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days. However, a loading dose of trastuzumab will not be given to patients who have received trastuzumab within 4 weeks of the first study dose of trastuzumab. These patients will receive trastuzumab at 6 mg/kg each cycle, including Cycle 1. Trastuzumab may also be given on a weekly basis at 2 mg/kg IV q 7 days, but only in the circumstance that trastuzumab infusion has been delayed, and weekly infusions are required to resynchronize the cycle length to 21 days, after discussion with the medical monitor. Trastuzumab infusion rates will be per institutional guidelines. Tucatinib (ONT-380) will be given PO BID at a dose dependent upon the dosing cohorts to which the patient is enrolled.

There will be 3-6 evaluable patients enrolled in each cohort in the dose escalation phase, unless that dose is found to be intolerable prior to completion of enrollment. At least 6 evaluable patients are to be treated at a dose level in order for an MTD/RP2D to be determined.

The MTD/RP2D of tucatinib (ONT-380) to be used in combination with either capecitabine alone (Combination 1) or trastuzumab alone (Combination 2) will be determined prior to evaluating tucatinib (ONT-380) in combination with both capecitabine and trastuzumab (Combination 3). If Combination 1 and Combination 2 are found to be tolerable, then tucatinib (ONT-380) will be evaluated in Combination 3, using the lowest MTD/RP2D or other SMC-recommended dose of tucatinib (ONT-380) determined for either of the two drug combinations. This will be followed by enrollment of an expansion cohort of patients treated at the MTD/RP2D for Combination 3. Additional expansion cohorts for either Combination 1 (tucatinib (ONT-380) and capecitabine) or Combination 2 (tucatinib (ONT-380) and trastuzumab) may also be enrolled.

Provided that only seven dose cohorts are needed for dose escalation and only the expansion cohort for Combination 3 is enrolled, up to 66 evaluable patients may be enrolled. Additional patients may be enrolled if additional expansion cohorts are opened.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Patients must meet the following criteria to be eligible for the study:

  1. Metastatic breast cancer, documented as HER2+ by fluorescence in situ hybridization (FISH) and/or 3+ staining by immunohistochemistry (IHC).
  2. Progressive disease, with a history of prior treatment with both trastuzumab and T-DM1 (unless deemed intolerant to or ineligible for T-DM1 by the investigator) for metastatic disease.
  3. ≥ 18 years at time of consent.
  4. If female and of child-bearing potential, has negative pregnancy test within 14 days prior to treatment.
  5. If a sexually active male or a sexually active female of child-bearing potential, agrees to use dual (two concurrent) forms of medically accepted contraception from the time of consent until 6 months after the last dose of ONT-380, capecitabine, or trastuzumab, whichever is longest.
  6. Signed an informed consent document that has been approved by an institutional review board or independent ethics committee (IRB/IEC).
  7. Must have target or non-target lesions as per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.
  8. All toxicity related to prior cancer therapies must have resolved to ≤ Grade 1, with the following exceptions: alopecia; neuropathy, which must have resolved to ≤ Grade 2; and congestive heart failure (CHF), which must have been ≤ Grade 1 in severity at the time of occurrence and must have resolved completely.
  9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening.
  10. In the opinion of the Investigator, life expectancy > 6 months.
  11. Adequate hematologic function as defined by:

    1. Hemoglobin ≥ 9 g/dL
    2. Absolute neutrophil count (ANC) ≥ 1000 cells/μL
    3. Platelets ≥ 100,000/μL
  12. Adequate hepatic function as defined by the following:

    1. Total bilirubin ≤ 1.5 X upper limit of normal (ULN), unless a known history of Gilbert's disease
    2. Transaminases (aspartate aminotransferase/serum glutamic oxaloacetic transaminase [AST/SGOT] and alanine aminotransferase/serum glutamic pyruvic transaminase [ALT/SGPT]) ≤ 2.5 X ULN (< 5 X ULN if liver metastases are present)
  13. International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 X ULN unless on medication known to alter INR and aPTT.
  14. Creatinine clearance ≥ 50 mL/min.
  15. Left ventricular ejection fraction (LVEF) must be within institutional limits of normal as assessed by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) documented within 4 weeks prior to first dose of study drug.

Exclusion Criteria

Patients will be excluded from the study for any of the following reasons:

  1. Medical, social, or psychosocial factors that, in the opinion of the Investigator, could impact safety or compliance with study procedures.
  2. Patient is breastfeeding.
  3. Previous treatment with any experimental agent within 14 days or five half-lives of study treatment, whichever is greater.
  4. Previous treatment with trastuzumab or other antibody-based therapy within three weeks of starting study treatment or with chemotherapy or hormonal cancer therapy within two weeks of starting study treatment.
  5. Previous treatment with cumulative dose of doxorubicin > 360 mg/m2 or previous treatment with another anthracycline with cumulative dose equivalent to > 360 mg/m2 doxorubicin.
  6. Previous treatment with:

    1. Capecitabine for metastatic disease at any time, for patients assigned to cohorts using capecitabine plus ONT-380 (Combination 1) or capecitabine plus trastuzumab plus ONT-380 (Combination 3). However, patients who have previous treatment with capecitabine for metastatic disease are eligible for enrollment into cohorts using trastuzumab plus ONT-380 (Combination 2). Patients who have received capecitabine for adjuvant or neoadjuvant treatment at least 12 months prior to starting study treatment are eligible to enroll into all cohorts (Combination 1, 2, or 3).
    2. Any small molecule HER2 inhibitors including (but not limited to) lapatinib, neratinib, or afatinib within the last 4 weeks prior to initiation of study therapy.
  7. CNS disease:

    1. Patients with leptomeningeal disease are excluded.
    2. Dose escalation and expansion cohorts: Patients with symptomatic CNS metastases are excluded. Patients with treated CNS metastases or untreated asymptomatic CNS metastases not requiring immediate local therapy may be eligible. Enrollment of patients with metastases must be approved by the study medical monitor.
    3. Optional CNS disease expansion cohorts: Patients with untreated asymptomatic CNS metastases not requiring immediate local therapy or patients with progressive CNS disease following local therapy may be eligible with medical monitor approval.
  8. History of allergic reactions to compounds of similar chemical or biological composition to capecitabine (for patients assigned to Combination 1 or 3 only), trastuzumab (for patients assigned to Combination 2 or 3 only), or ONT-380, except for a history of Grade 1 or Grade 2 Infusion Related Reaction to trastuzumab, which has been successfully managed.
  9. Patients with uncorrectable electrolyte abnormalities.
  10. Known to be HIV positive. HIV testing is not required for those patients who are not known to be positive.
  11. Known carrier of Hepatitis B and / or Hepatitis C (whether active disease or not).
  12. Known liver disease, autoimmune hepatitis, or sclerosing cholangitis.
  13. Inability to swallow pills or any significant gastrointestinal diseases, which would preclude adequate absorption of oral medications.
  14. Use of a strong CYP3A4 inhibitor or inducer within three elimination half-lives of the inhibitor or inducer prior to the start of study treatment.
  15. Use of a strong CYP2C8 inducer or inhibitor within three elimination half-lives of the inducer or inhibitor prior to the start of study treatment. (See Appendix F).
  16. Radiotherapy within 14 days of first dose of ONT-380; patient must have recovered from acute effects of radiotherapy to baseline.
  17. Known impaired cardiac function or clinically significant cardiac disease such as ventricular arrhythmia requiring therapy, congestive heart failure, and uncontrolled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg on antihypertensive medications).
  18. Myocardial infarction or unstable angina within 6 months prior to the first dose of study drug.
  19. Patient with known dihydropyrimidine dehydrogenase deficiency (for patients assigned to Combination 1 or 3 only).
  20. Patient requiring warfarin therapy with known history of difficulty in management of maintaining INR within therapeutic range. Patients on warfarin may be included if on a stable dose with a therapeutic INR.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02025192

Locations
United States, Colorado
University of Colorado
Aurora, Colorado, United States, 80045
United States, Oregon
Providence Cancer Center
Portland, Oregon, United States, 97213
United States, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Washington
Northwest Medical Specialties
Tacoma, Washington, United States, 98405
Sponsors and Collaborators
Cascadian Therapeutics Inc.
Investigators
Study Director: Luke Walker, MD Cascadian Therapeutics Inc.
  More Information

Responsible Party: Cascadian Therapeutics Inc.
ClinicalTrials.gov Identifier: NCT02025192     History of Changes
Other Study ID Numbers: ONT-380-005
Study First Received: December 17, 2013
Last Updated: August 10, 2017

Keywords provided by Cascadian Therapeutics Inc.:
ONT-380
Capecitabine
Trastuzumab
Xeloda
Herceptin
HER2 positive breast cancer
Breast cancer
ARRY-380
Tucatinib

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Capecitabine
Trastuzumab
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents

ClinicalTrials.gov processed this record on September 21, 2017